These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30559064)

  • 1. Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons.
    Hamid AA; Morris MJ; Davis ID
    Eur Urol Focus; 2019 Mar; 5(2):165-167. PubMed ID: 30559064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations.
    Yu EY; Gillessen S; Mottet N
    Eur Urol Focus; 2019 Mar; 5(2):162-164. PubMed ID: 30287277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
    Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
    Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
    Scott LJ
    Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.
    Akaza H; Procopio G; Pripatnanont C; Facchini G; Fava S; Wheatley D; Leung KC; Butt M; Silva A; Castillo L; Karavasilis V; Ӧzatılgan A; Hitier S; Ecstein-Fraisse EB; Ӧzgüroḡlu M
    J Glob Oncol; 2018 Sep; 4():1-12. PubMed ID: 30260754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Review on quality of life in CRPC patients].
    Miller K
    Aktuelle Urol; 2017 May; 48(3):219-224. PubMed ID: 28614882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Castration-naive Metastatic Prostate Cancer.
    Hamilou Z; Baciarello G; Fizazi K
    Eur Urol Focus; 2017 Dec; 3(6):518-521. PubMed ID: 29500136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hormone-naïve metastatic prostate cancer.
    Hamilou Z; Saad F; Fizazi K
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
    Grisay G; Lavaud P; Fizazi K
    Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
    Caffo O; Veccia A; Kinspergher S; Maines F
    Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term abiraterone withdrawal syndrome.
    Marin S; Querol R; Campins L; Miarons M; Font A; Lianes P
    J Clin Pharm Ther; 2018 Oct; 43(5):714-716. PubMed ID: 29722038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.
    Vicier C; Feng FY; Fizazi K
    Eur Urol Focus; 2019 Mar; 5(2):168-170. PubMed ID: 30745118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
    Geynisman DM; Ross EA; Plimack ER
    Eur Urol; 2015 Oct; 68(4):578-80. PubMed ID: 26116295
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
    Petrioli R; Francini E; Laera L; Fiaschi AI; Ponchietti R; Roviello G
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):439-45. PubMed ID: 26082421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer-The Forgotten Dance Partner?
    Klaassen Z; Wallis CJD; Fleshner NE
    JAMA Oncol; 2019 Feb; 5(2):144-145. PubMed ID: 30489621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.